Lercanidipine Orion (Lercanidipine Hydrochloride)

Lercanidipine is a calcium channel blocker used to manage hypertension by relaxing arterial smooth muscle and reducing peripheral resistance.

• Hypertension: reduces systolic and diastolic blood pressure, aiding in the prevention of cardiovascular complications.

• Lercanidipine selectively inhibits L-type calcium channels in vascular smooth muscle cells, which decreases calcium influx, leading to arterial vasodilation. This vasodilatory effect lowers peripheral vascular resistance and consequently reduces systemic blood pressure without significant negative inotropic effects on the heart.

Lercanidipine may cause a range of adverse reactions, from mild to serious. Monitoring for side effects is recommended during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower limbs.
• Dizziness: sensation of light‑headedness, especially on standing.
• Tachycardia: increased heart rate.
• Palpitations: awareness of heartbeats.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing faintness.
• Angioedema: swelling of face, lips, tongue, or throat.
• Myocardial infarction: rare occurrence of heart attack.
• Liver dysfunction: abnormal liver enzymes or hepatitis.
• Severe allergic reactions: rash, itching, or anaphylaxis.

Before initiating Lercanidipine therapy, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use with caution in patients with severe liver disease.
• Heart failure: evaluate risk of fluid retention and monitor cardiac status.
• Drug interactions: review concomitant medications that may affect blood pressure.
• Pregnancy and lactation: consider only if benefits outweigh potential risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
• Concomitant antihypertensives causing additive hypotension.
• Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.

• Diuretics: may enhance blood pressure‑lowering effect.
• Beta‑blockers: combined use may require dose adjustments.
• NSAIDs: may blunt antihypertensive response.